Dabrafenib
Sign in to save this workspacePrimary targets: BRAF · FDA status: FDA Approved
Selectivity scorecard
KISS
94.74
Gini
0.633
CATDS
0.011
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Dabrafenib. Strongest target: RAF1 at 99.8% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RAF1 | 99.8% | 0.2% |
| 2 | NEK9 | 99.7% | 0.3% |
| 3 | LIMK1 | 99.0% | 1.0% |
| 4 | LIMK2 | 98.9% | 1.1% |
| 5 | BRAF | 98.3% | 1.7% |
| 6 | TESK1 | 97.0% | 3.0% |
| 7 | EIF2AK2 | 96.6% | 3.4% |
| 8 | ZAK_MLTK | 96.4% | 3.6% |
| 9 | ARAF | 96.3% | 3.7% |
| 10 | RIPK3 | 96.0% | 4.0% |
| 11 | SIK1 | 96.0% | 4.0% |
| 12 | DDR2 | 95.4% | 4.6% |
| 13 | EIF2AK3 | 94.5% | 5.5% |
| 14 | LCK | 93.7% | 6.3% |
| 15 | PKCMU_PRKD1 | 93.3% | 6.7% |
| 16 | CSK | 92.7% | 7.3% |
| 17 | TESK2 | 92.4% | 7.6% |
| 18 | ALK6_BMPR1B | 92.3% | 7.7% |
| 19 | PKCNU_PRKD3 | 92.3% | 7.7% |
| 20 | NEK11 | 92.1% | 7.9% |
Selectivity landscape
Where Dabrafenib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Dabrafenib.
Annotations
Sign in to read and post annotations.
Loading…